预约演示
更新于：2024-12-27
Fusidic acid
夫西地酸
更新于：2024-12-27
概要
基本信息
结构/序列
分子式C31H48O6 |
InChIKeyIECPWNUMDGFDKC-MZJAQBGESA-N |
CAS号6990-06-3 |
关联
14
项与 夫西地酸 相关的临床试验NCT06695143
Antimicrobial Adjuvants to Revert the Imbalance of Skin Microbiota for Improved Outcomes of Complicated Cutaneous Leishmaniasis Treatment in Ethiopia
CTRI/2024/02/062657
Exploring the Feasibility of fusidic acid phonophoresis as complementary therapy on bacterial analysis in chronic rhinosinusitis a randomised controlled trial - nil
CTRI/2022/09/045794
A comparative study of in vitro efficacy of ozenoxacin vs mupirocin vs fusidic acid against gram positive clinical isolates
100 项与 夫西地酸 相关的临床结果
登录后查看更多信息
100 项与 夫西地酸 相关的转化医学
登录后查看更多信息
100 项与 夫西地酸 相关的专利（医药）
登录后查看更多信息
2,129
项与 夫西地酸 相关的文献（医药）2024-10-09Nederlands tijdschrift voor geneeskunde
[Special lesion on back of the hand].
Article
作者: van den Oord, Lotte J ; de Mare, Saskia
A 74-year-old man, previously healthy, presented at the Dermatology department with an asymptomatic hand lesion persisting for two months. The general practitioner initially treated the lesion with betamethasone and fusidic acid cream. Examination revealed a 3 cm livid plaque with central crusts. A biopsy confirmed cutaneous leishmaniasis tropica. The patient travelled to Greece, Spain, and Southern France before the lesion occurred, which is consistent with the endemicity of leishmaniasis in the Mediterranean. Treatment involved cryotherapy and antimony injections, resulting in lesion resolution after two sessions. This case underscores the importance of considering travel history and endemic diseases in diagnosing and managing dermatological conditions, especially in regions prone to specific infections.
2024-10-08ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
The fungal natural product fusidic acid demonstrates potent activity against
Mycoplasma genitalium
Article
作者: Wood, Gwendolyn E. ; Peramuna, Thilini ; Aguila, Laarni Kendra T. ; Wendt, Karen L. ; Lee, Jin Woo ; Cichewicz, Robert H. ; Calderon, Claire L. ; Kim, Caroline M.
ABSTRACT:
Antimicrobial resistance is extremely common in
Mycoplasma genitalium
, a frequent cause of urethritis in men and cervicitis, vaginitis, and pelvic inflammatory disease in women. Treatment of
M. genitalium
infections is difficult due to intrinsic and acquired resistance to many antibiotic classes. We undertook a program to identify novel antimicrobials with activity against
M. genitalium
from fungal natural products. Extracts of
Ramularia coccinea
contained a molecule with potent activity that was subsequently identified as fusidic acid, a fusidane-type antibiotic that has been in clinical use for decades outside the United States. We found that minimum inhibitory concentrations of fusidic acid ranged from 0.31 to 4 µg/mL among 17
M
.
genitalium
strains including laboratory-passaged and low-passage clinical isolates. Time-kill data indicate that bactericidal killing occurs when
M. genitalium
is exposed to ≥10 µg/mL for 48 h, comparing favorably to serum concentrations obtained from typical loading dose regimens. Resistance to fusidic acid was associated with mutations in
fusA
consistent with the known mechanism of action in which fusidic acid inhibits protein synthesis by binding to elongation factor G. Interestingly, no mutants resistant to >10 µg/mL fusidic acid were obtained and a resistant strain containing a F435Y mutation in FusA was impaired for growth
in vitro
. These data suggest that fusidic acid may be a promising option for the treatment of
M. genitalium
infections.
2024-10-08ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
IMT-P8 potentiates Gram-positive specific antibiotics in intrinsically resistant Gram-negative bacteria
Article
作者: Nandanwar, Hemraj ; Singh, Vidhu
ABSTRACT:
Gram-negative bacteria (GNB) pose a major global public health challenge as they exhibit a remarkable level of resistance to antibiotics. One of the factors responsible for promoting resistance against a wide range of antibiotics is the outer membrane (OM) of Gram-negative bacteria. The OM acts as a barrier that prevents the entry of numerous antibiotics by reducing their influx (due to membrane impermeability) and enhancing their efflux (with the help of efflux pumps). Our study focuses on analyzing the effect of IMT-P8, a cell-penetrating peptide (CPP), to enhance the influx of various Gram-positive specific antibiotics in multi-drug resistant Gram-negative pathogens. In the mechanistic experiments, IMT-P8 permeabilizes the OM at the same concentrations at which it enhances the activity of various antibiotics against GNB. Cytoplasmic membrane permeabilization was also observed at these concentrations, indicating that IMT-P8 acts on both the outer and cytoplasmic membranes. IMT-P8 interferes with the intrinsic resistance mechanism of GNB and has the potential to make Gram-positive specific antibiotics effective against GNB. IMT-P8 extends the post-antibiotic effect and in combination with antibiotics shows anti-persister activity. The IMT-P8/fusidic acid combination is effective in eliminating intracellular pathogens. IMT-P8 with negligible toxicity displayed good efficacy in murine lung and thigh infection models. Based on these findings, IMT-P8 is a potential antibiotic adjuvant to treat Gram-negative bacterial infections that pose a health hazard.
100 项与 夫西地酸 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 细菌性结膜炎 | 英国 | 1987-08-10 | |
| 细菌感染 | 加拿大 | 1984-12-31 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 细菌性皮肤疾病 | 临床2期 | 美国 |  Arrevus, Inc.初创企业 | 2009-08-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 49 | 選遞窪窪築築蓋廠窪網(蓋繭網衊遞壓簾網獵艱) = Adverse reactions occurred in 27.3% (15 TC), mostly within the first 4 weeks of treatment (63.6%). The majority were gastrointestinal symptoms (21.8%, 12 TC), which led to discontinuation of treatment in 12.7%. 艱顧憲夢製鬱膚簾積壓 (衊範蓋願醖遞憲構選顧 ) | - | 2022-09-07 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用